scholarly journals A Case of Multiple Pancreatic Metastases from Renal Cell Carcinoma Treated by Total Pancreatectomy.

1996 ◽  
Vol 29 (11) ◽  
pp. 2175-2179 ◽  
Author(s):  
Kazuhide Iwakawa ◽  
Yasushi Matsumoto ◽  
Jyota Watanabe ◽  
Yoshito Ono ◽  
Yasuyuki Shimahara ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Total Pancreatectomy ◽  
Pancreatic Metastases

scholarly journals A case of seventeen pancreatic metastases from renal cell carcinoma resected by total pancreatectomy

Suizo ◽  
2011 ◽  
Vol 26 (4) ◽  
pp. 517-523
Author(s):  
Eiji HIGAKI ◽  
Naoto GOTOHDA ◽  
Masaru KONISHI ◽  
Shinichiro TAKAHASHI ◽  
Yuichiro KATO ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Total Pancreatectomy ◽  
Pancreatic Metastases

scholarly journals Multiple Pancreatic Metastases from Renal Cell Carcinoma Treated with Total Pancreatectomy after Chemotherapy: A Case Report

2017 ◽  
Vol 42 (5) ◽  
pp. 853-859
Author(s):  
Yujiro Tsuda ◽  
Terumasa Yamada ◽  
Hiroaki Itakura ◽  
Hirotoshi Takayama ◽  
Masami Ueda ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Case Report ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Total Pancreatectomy ◽  
Pancreatic Metastases

scholarly journals Pancreatic ductal adenocarcinoma concomitant with pancreatic metastases of clear-cell renal cell carcinoma: a case report

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Lena Haeberle ◽  
Melanie Busch ◽  
Julian Kirchner ◽  
Georg Fluegen ◽  
Gerald Antoch ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Ductal Adenocarcinoma ◽  
Special Role ◽  
Cell Renal Cell Carcinoma ◽  
Pancreatic Metastases

Abstract Background Metastatic spread to the pancreas is a rare event. Renal cell carcinoma represents one possible site of origin of pancreatic metastases. Renal cell carcinoma often metastasizes late and exclusively to the pancreas, suggesting a special role of renal cell carcinoma among primaries metastasizing to the pancreas. Even rarer, renal cell carcinoma may occur simultaneously with pancreatic ductal adenocarcinoma. Case presentation We present the case of a 78-year-old male Caucasian patient with a history of clear-cell renal cell carcinoma treated with oncological left nephrectomy 20 years before. The patient was diagnosed with pancreatic ductal adenocarcinoma by fine-needle aspiration cytology. At our institution, he received neoadjuvant therapy with folic acid, fluorouracil, irinotecan, oxaliplatin for borderline-resectable pancreatic ductal adenocarcinoma, and subsequently underwent total pancreatectomy. Upon resection, pancreatic ductal adenocarcinoma as well as two metachronous metastases of clear-cell renal cell carcinoma occurring simultaneously and cospatially with pancreatic ductal adenocarcinoma were diagnosed in the pancreatic body. Conclusions Renal cell carcinoma metastases of the pancreas are rare and often occur decades after the initial diagnosis of renal cell carcinoma. The combination of renal cell carcinoma metastases and pancreatic ductal adenocarcinoma is even rarer. However, the possibility should be considered by clinicians, radiologists, and pathologists. The special role of renal cell carcinoma as a site of origin of pancreatic metastasis should be further elucidated.

scholarly journals Imaging of pancreatic metastases from renal cell carcinoma

2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Matteo Vincenzi ◽  
Giulio Pasquotti ◽  
Roberta Polverosi ◽  
Claudio Pasquali ◽  
Fabio Pomerri
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Pancreatic Metastases

scholarly journals Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis

PLoS ONE ◽  
2016 ◽  
Vol 11 (4) ◽  
pp. e0151662 ◽  
Author(s):  
Paolo Grassi ◽  
Ludovic Doucet ◽  
Palma Giglione ◽  
Viktor Grünwald ◽  
Bohuslav Melichar ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Retrospective Analysis ◽  
Renal Cell ◽  
Clinical Impact ◽  
Pancreatic Metastases

scholarly journals Pancreatic Metastases from Renal Cell Carcinoma Presenting as Intestinal Obstruction

2010 ◽  
Vol 66 (3) ◽  
pp. 275-277
Author(s):  
RA George ◽  
J Debnath ◽  
SS Kumar ◽  
D Banerjee ◽  
R Bhardwaj ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Intestinal Obstruction ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Pancreatic Metastases

Late pancreatic metastases from renal cell carcinoma: A case report

2016 ◽  
Vol 78 (5) ◽  
pp. 37
Author(s):  
O. G. Polushin ◽  
K. V. Fedosenko ◽  
E. V. Ponomareva ◽  
R. E. Topuzov ◽  
O. N. Kislitsyna
Keyword(s):  
Renal Cell Carcinoma ◽  
Case Report ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Pancreatic Metastases

Endoscopic Ultra Sound-guided RadioFrequency Ablation (EUSRFA) as focal treatment for pancreatic metastases from renal cell carcinoma: A monocentric experience.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 695-695
Author(s):  
Brice Chanez ◽  
Fabrice Caillol ◽  
Jean-Philippe Ratone ◽  
Erwan Bories ◽  
Christian Pesenti ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Radiofrequency Ablation ◽  
Ct Scan ◽  
Cell Carcinoma ◽  
Local Control ◽  
Renal Cell ◽  
Kinase Inhibitor ◽  
Complete Response ◽  
Ultra Sound ◽  
Pancreatic Metastases

695 Background: Pancreatic metastases (PM) from renal cell carcinoma (RCC) are rare but associated with long survival. The usual management of PM is surgery or tyrosine kinase inhibitor (TKI) with sides effects. Endoscopic radiofrequency ablation (EUSRFA) is an innovative approach to focally treat deep metastasis and could be a relevant technic to control PM from RCC. Methods: This analysis addressed the local control and toxicity in patients treated by EUSRFA for progressive PM from RCC. EUSRFA was done with a linear EUS scope and a 19 G needle delivering short ablation time. Response was assessed by CT-scan using both size and contrast enhancement of the PM treated every 2 to 3 months. Results: 8 pts from Paoli-Calmettes Institute (France) were treated between May 2017 and August 2019. Age was 70.5y [61-75], 5/8 female, ECOG 0-1 (100%). The median time from diagnosis to PM was 14.5 years [9.35-22.18], median number of PM was 2 [1-3], 6/8 was documented by histology and all were classified as progressive before EUSRFA. PM localizations was: head in 40%, body 40% and average size was 14 mm [4 - 35]. 75% of pts (6/8) had other mRCC spread, 5/8 had received systemic treatment and 2 were on therapy at EUSRFA time. 3 pts had EUSRFA as the only treatment for RCCm. We performed 18 EUSRFA procedures over 16 PM. Patient received in median 2 EUSRFA sessions [1-3]. Follow up of 22.4 months [2.3-42.6], 50% of treated PM was evaluated as complete response, 17.5% as partial response and 20% as stable disease at the last CT-scan evaluation. 2 pts were considered as progressive disease and PM focal control was 87.5%. One patient treated with TKI during EURFA developed a paraduodenal abscess 2 months after EUSRFA. Another patient with biliary prothesis developed hepatic abscesses few days after EUSRFA. No other acute side effects were experienced. Interestingly, all PM treated with diameter of < 20mm was locally control versus only 75% of PM> 20mm. Conclusions: Though larger studies have to corroborate our data, EUSRFA is feasible and displays a good local control for PM. It could be a valuable option, less morbid than pancreas resection, for well selected patients with progressive PM.

Sign in / Sign up

Export Citation Format

Share Document